Thymosin Beta 4 vs TB-500: Names, Sequences, and Research Distinctions

TLDR

The clearest answer to thymosin beta 4 vs TB-500 is that they should not automatically be treated as the same molecule. Mature human thymosin beta-4, or Tβ4, is a 43-amino-acid peptide. The material identified as TB-500 in analytical and anti-doping research is the N-terminally acetylated seven-residue sequence Ac-LKKTETQ, corresponding to one region within Tβ4. A commercial label saying “TB-500” does not, by itself, prove which sequence is present.

This molecular distinction changes how the evidence should be read. Human studies of full-length synthetic Tβ4 do not establish the safety, pharmacokinetics, efficacy, or clinical equivalence of Ac-LKKTETQ. Conversely, analytical, animal, or cell-based studies of the short fragment cannot be presented as studies of full-length Tβ4.

Thymosin beta 4 vs TB-500 at a glance

Feature	Full-length thymosin beta-4	TB-500 as identified in analytical research
Common names	Thymosin beta-4, Tβ4, TB4	TB-500, Ac-LKKTETQ
Sequence length	43 residues in the mature peptide	7 residues
Sequence relationship	Contains the LKKTETQ region	Corresponds to a short region within Tβ4
Numbering	LKKTETQ is residues 17–23 in mature Tβ4	Sometimes called residues 18–24 when initiator methionine is counted
Relevant human research	Published studies have evaluated full-length synthetic Tβ4 in specific formulations	The supplied evidence does not establish comparable human exposure data for Ac-LKKTETQ
Identity requirement	Expected full-length sequence and associated analytical profile	Expected Ac-LKKTETQ sequence, including N-terminal acetylation
Evidence transfer	Results apply to the studied full-length formulation and conditions	Cannot inherit full-length Tβ4 findings merely because it shares seven residues

What is full-length thymosin beta-4?

TMSB4X is the human gene associated with thymosin beta-4. The translated reference sequence contains an initiator methionine, producing a 44-residue representation at the protein-sequence level. Biochemical characterization describes the mature thymosin beta-4 peptide as 43 amino acids after removal of that initiator methionine.

Using one-letter amino-acid notation, the mature 43-residue sequence is Ac-SDKPDMAEIEKFDKSKLKKTETQEKNP LPSKETIEQEKQAGES, conventionally written without the visual space as Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES. The “Ac” denotes N-terminal acetylation. The LKKTETQ segment appears within this longer molecule rather than representing the complete peptide.

This distinction between a translated gene product and a mature processed peptide is not merely a naming technicality. Residue numbering, calculated molecular composition, expected mass, fragmentation behavior, and analytical interpretation all depend on which molecular form is being discussed.

What does TB-500 mean?

A 2012 synthesis and characterization study identified TB-500 as the N-terminally acetylated thymosin beta-4 fragment Ac-LKKTETQ. The paper is particularly useful because it addresses chemical identity rather than inferring identity from a trade-style name. Readers can review the original TB-500 characterization study for the analytical context.

Under that research definition, TB-500 is not an alternative spelling for the complete 43-residue peptide. It is a seven-residue fragment derived from a region of Tβ4. The shared subsequence establishes a structural relationship, but not molecular identity or functional equivalence.

Commercial nomenclature is less controlled than gene or sequence nomenclature. Different sellers or informal discussions may use “TB-500” loosely, including as though it were synonymous with full-length Tβ4. The name alone therefore cannot resolve what is in a vial or analytical sample. That requires a stated structure and documentation connected to the specific lot.

Why the fragment may be numbered 17–23 or 18–24

The apparent numbering conflict comes from two valid but different starting points. In the mature 43-residue peptide, LKKTETQ occupies positions 17 through 23. If a source counts the translated 44-residue sequence beginning with initiator methionine, every subsequent residue shifts by one position, placing the same segment at positions 18 through 24.

A careful report should state which reference sequence it uses. “Tβ4 residues 17–23” and “residues 18–24 of the translated sequence” can describe the same seven amino acids. Without that context, the numbering may look like evidence for two different fragments when it is actually a bookkeeping difference.

Why the “Ac” in Ac-LKKTETQ matters

Acetylation changes the chemical structure of a peptide’s N-terminus. Ac-LKKTETQ and unmodified LKKTETQ therefore have different elemental compositions and expected molecular masses. They may also behave differently during chromatography, mass-spectrometric fragmentation, enzymatic degradation, or biological assays.

For full-length mature Tβ4, acetylation applies to the N-terminal serine of the complete sequence. For the short TB-500 fragment, it applies to the leucine that becomes the fragment’s new N-terminus. Describing both molecules as acetylated does not erase their difference in length, sequence context, or molecular identity.

The research records answer different questions

Published human research has evaluated full-length synthetic thymosin beta-4 in particular formulations and clinical settings. One randomized, placebo-controlled study administered intravenous full-length synthetic Tβ4 to healthy volunteers. Other studies evaluated a 0.1% Tβ4 ophthalmic solution in dry eye and topical Tβ4 in venous ulcers.

These studies should not be grouped into a single general claim about “TB-500.” They involved full-length Tβ4, distinct routes and formulations, different populations, and different endpoints. The dry-eye Phase II trial also illustrates why headline summaries are insufficient: its specified primary endpoints were not statistically different at the stated visit, while some secondary outcomes favored Tβ4.

A separate ClinicalTrials.gov record, NCT02600429, concerns RGN-259 ophthalmic solution for neurotrophic keratopathy. It is another formulation-specific full-length Tβ4 program, not a trial of the seven-residue Ac-LKKTETQ fragment.

Evidence concerning the short fragment

The research record for Ac-LKKTETQ includes chemical characterization and anti-doping analysis. An equine study examined TB-500 and metabolites in horse urine and plasma using liquid chromatography–mass spectrometry. A 2024 paper assessed TB-500 and metabolites in in-vitro systems and rats, including a fibroblast wound-healing assay.

These experiments have legitimate analytical and preclinical value, but they do not establish therapeutic outcomes in people. Equine detection research answers questions about metabolism and analytical detection in horses. Cell assays test behavior under controlled in-vitro conditions. Rat experiments examine effects and disposition in that animal model. For a broader framework, see how in-vitro and in-vivo peptide studies answer different questions.

The important distinction is that a shared sequence motif does not license evidence transfer. Full-length Tβ4 may have structural interactions, degradation pathways, distribution, and pharmacokinetics that cannot be reproduced by an isolated seven-residue fragment. Any functional similarity must be demonstrated experimentally rather than assumed from sequence overlap.

How to verify whether a research material is Tβ4 or TB-500

A stated purity percentage is not enough. Chromatographic purity estimates how much of the detected chromatographic signal is associated with a selected peak under a particular method. It does not independently establish that the peak is full-length Tβ4, Ac-LKKTETQ, or another compound.

An identity review should look for the following:

A lot number connecting the received material to the analytical report.
The complete stated sequence, not only the names “TB-500,” “TB4,” or “thymosin beta-4.”
An explicit statement of N-terminal acetylation and any other modifications.
An expected molecular formula or mass calculated for the stated molecular form.
Observed intact-mass data consistent with the expected analyte.
Method details showing the ionization and mass-spectrometric approach used.
Peptide mapping or LC-MS/MS fragmentation evidence when sequence-level confirmation is needed.
Chromatographic results with the method, detection conditions, retention information, integration approach, and relevant impurity reporting.
Identification of the laboratory and a clear connection among the sample, report, product, and lot.

Mass consistency is useful identity evidence, but it is not a complete purity assessment. HPLC can characterize a chromatographic profile, but it cannot by itself establish molecular identity, sterility, endotoxin status, peptide content, or biological potency. The practical framework is explained further in peptide identity versus purity.

For this comparison, the expected difference is substantial: one candidate is a mature 43-residue peptide, while the other is an acetylated seven-residue fragment. A report that gives only “99% purity” without a sequence, modification state, observed mass, and lot linkage leaves the central identity question unanswered.

FDA and anti-doping context

FDA’s compounding-safety material specifically lists “Thymosin beta-4, fragment (LKKTETQ), also known as TB-500.” It discusses potential immunogenicity concerns associated with aggregation and peptide-related impurities in compounded products containing this fragment. FDA also states in that material that it had not identified human exposure data for drug products containing the fragment. This is a statement about LKKTETQ/TB-500 in a compounding context, not a summary of the separate full-length Tβ4 research record.

Anti-doping status is also explicit but date-sensitive. WADA’s 2026 Prohibited List names thymosin-β4 and its derivatives, including TB-500, under the growth factors and growth-factor modulators category and classifies them as prohibited at all times. The list in force for the relevant year and jurisdiction should always be checked directly because prohibited lists are updated.

Neither regulatory risk discussion nor anti-doping classification proves that two substances are chemically identical. These frameworks may group a parent peptide and derivatives together for policy purposes while analytical chemistry continues to distinguish their exact sequences and modifications.

Frequently asked questions

Is TB-500 the same molecule as thymosin beta-4?

Not under the definition established in the cited analytical literature. Full-length mature Tβ4 contains 43 amino acids, whereas TB-500 was identified as the seven-residue N-terminally acetylated fragment Ac-LKKTETQ. Commercial naming is inconsistent, so the exact material still requires lot-specific verification.

Which molecule has been studied in humans?

The human studies discussed here evaluated full-length synthetic thymosin beta-4 in specific intravenous, ophthalmic, or topical formulations. They were not studies of Ac-LKKTETQ identified as TB-500.

Can a TB-500 purity result prove that the material is Ac-LKKTETQ?

No. A purity result without adequate identity evidence can show that one chromatographic component predominates while leaving the component’s molecular identity unresolved. Sequence information, modification state, mass spectrometry, method details, and lot linkage are needed.

Does an animal or cell study establish that TB-500 works in people?

No. Such studies can support analytical, mechanistic, metabolism, or proof-of-concept conclusions within their models. They do not establish human clinical effectiveness, an appropriate formulation, or human safety.

Can full-length Tβ4 results be applied to the fragment because it contains the active region?

Not without direct evidence. Calling a sequence an “active region” may describe a hypothesis or an assay result, but an isolated fragment can differ from the parent peptide in conformation, stability, distribution, metabolism, target interactions, and functional effects.

Conclusion

The most useful way to interpret thymosin beta 4 vs TB-500 is at the sequence level. Mature Tβ4 is a 43-residue peptide. TB-500, as characterized in the cited analytical research, is Ac-LKKTETQ, a seven-residue acetylated fragment corresponding to positions 17–23 of mature Tβ4. The alternative 18–24 numbering reflects inclusion of the translated initiator methionine.

That molecular distinction should control both evidence interpretation and material verification. Human results from full-length Tβ4 formulations cannot be assigned to Ac-LKKTETQ, while animal and in-vitro fragment studies cannot establish human outcomes. For any research material, begin with the stated sequence and modification, then examine lot-linked mass-spectrometric and chromatographic documentation. The name on the label is the starting claim, not the analytical conclusion.